Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia
- Authors
- Mitsudomi, T[Mitsudomi, Tetsuya]; Tan, D[Tan, Daniel]; Yang, JCH[Yang, James Chih-Hsin]; Ahn, MJ[Ahn, Myung-Ju]; Batra, U[Batra, Ullas]; Cho, BC[Cho, Byoung-Chul]; Cornelio, G[Cornelio, Gerardo]; Lim, T[Lim, Tony]; Mok, T[Mok, Tony]; Prabhash, K[Prabhash, Kumar]; Reungwetwattana, T[Reungwetwattana, Thanyanan]; Ren, SX[Ren, Sheng-Xiang]; Singh, N[Singh, Navneet]; Toyooka, S[Toyooka, Shinichi]; Wu, YL[Wu, Yi-Long]; Yang, PC[Yang, Pan-Chyr]; Yatabe, Y[Yatabe, Yasushi]
- Issue Date
- Apr-2023
- Publisher
- ELSEVIER SCIENCE INC
- Keywords
- Non-small cell lung cancer; ctDNA; Biomarkers; Adenocarcinoma; Squamous carcinoma; Liquid biopsy
- Citation
- JOURNAL OF THORACIC ONCOLOGY, v.18, no.4, pp.436 - 446
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF THORACIC ONCOLOGY
- Volume
- 18
- Number
- 4
- Start Page
- 436
- End Page
- 446
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/102829
- DOI
- 10.1016/j.jtho.2022.10.021
- ISSN
- 1556-0864
- Abstract
- Introduction: Most published guidelines for genomic biomarker testing in NSCLC reflect the disease epidemiology and treatments readily available in Europe and North America. Nevertheless, 60% of annual global NSCLC cases occur in Asia, where patient characteristics, tumor molecular profiles, and treatments vary greatly from the Western world. For example, mutations in the EGFR occur at a higher prev-alence in Asia than in other world regions. Although medical associations such as the International Association for the Study of Lung Cancer, European Society for Medical Oncology, and American Society of Clinical Oncology have described principles for tumor genomic biomarker testing in NSCLC, there is a need for recommendations specific for Asia.Methods: This report provides consensus recommenda-tions for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations in EGFR, ALK, ROS1, and others are discussed.Results: These recommendations are divided into non -metastatic and metastatic forms of adenocarcinoma and squamous cell carcinoma. Owing to the higher prevalence of EGFR mutations in Asia, the experts emphasized the need for EGFR testing to include not just common mutations (exon 19 deletions and L858R substitutions) but also other uncommon EGFR mutations. In addition to the assessment of biomarkers in the tumor tissue, the role of assessing tumor biomarkers by liquid biopsy is discussed.Conclusion: This consensus provides practical recommen-dations for biomarker testing in nonmetastatic and meta-static Asian NSCLC patients.(c) 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.